Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

BAY 2927088 is an oral, reversible tyrosine kinase inhibitor specifically targeting activating HER2 (ERBB2) mutations. Previous studies have demonstrated its manageable safety profile and encouraging preliminary anti-tumour activity in patients with advanced NSCLC harbouring HER2 mutations.

The drug has received Breakthrough Therapy designation from both the US Food and Drug Administration and the Chinese Center for Drug Evaluation for patients with unresectable or metastatic NSCLC who have previously undergone therapy.

Xiuning Le, M.D., Ph.D.,  The University of Texas MD Anderson Cancer Center, Houston, TX and National University Hospital, Seoul/KR presented updated results from the expansion cohort of the ongoing Phase I/II SOHO-01 study.

The SOHO-01 study is an ongoing, open-label, multicenter Phase I/II study. The expansion cohort specifically enroled patients with advanced HER2-mutant NSCLC who had not received HER2-targeted therapy.

Patients with advanced NSCLC harbouring a HER2-activating mutation who had experienced disease progression after at least one prior systemic therapy for advanced disease were administered oral BAY 2927088 at a dosage of 20 mg twice daily. The study's objectives were to assess the safety and antitumor activity of BAY 2927088, with efficacy evaluated per RECIST v1.1 and safety assessed using MedDRA v27.0.

Dr. Le and her colleague enroled a total of 44 patients, who had a median age of 62 years-- 63.6% were female, 70.5% had never smoked, and 54.5% had received two or more lines of therapy. The researchers followed up on the patients for 10.9 months.

Of the 43 patients evaluable for efficacy, Dr. Le reported a confirmed objective response rate of 72.1% (n=31; 95% CI 56.3, 84.7), including one complete response (2.3%). The median duration of response and progression-free survival were 8.7 months (95% CI 4.5, not estimable) and 7.5 months (95% CI 4.4, 12.2), respectively.

In a subgroup analysis, patients with tumours harbouring HER2 Y772_A775dup (YVMA) exon 20 insertion mutations had an objective response rate of 90.0%. Among the eight patients with previously treated and asymptomatic brain metastases, the objective response rate was 62.5%.

Dr. Le reported that the safety profile of BAY 2927088 was manageable and consistent with previous reports, reinforcing its potential as a promising therapy for patients with advanced NSCLC harbouring HER2 mutations.

“These data from the SOHO-01 study underscore the potential of BAY 2927088 as a treatment for patients with advanced NSCLC harbouring HER2 mutations,” said Dr. Le. “The drug demonstrated substantial and durable responses in a heavily pretreated patient population, with a manageable safety profile. These findings support the continued investigation of BAY 2927088 in this patient group, especially in light of its recent Breakthrough Therapy designation by the FDA.”

Source: International Association for the Study of Lung Cancer